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Computational Assay of H7N9 Influenza
Neuraminidase Reveals R292K Mutation
Reduces Drug Binding Affinity
Christopher J. Woods1, Maturos Malaisree1, Ben Long2, Simon McIntosh-Smith2 & Adrian J. Mulholland1
1Centre for Computational Chemistry, School of Chemistry, University of Bristol, Bristol, UK, 2Department of Computer Science,
University of Bristol, Bristol, UK.
The emergence of a novel H7N9 avian influenza that infects humans is a serious cause for concern. Of the
genome sequences of H7N9 neuraminidase available, one contains a substitution of arginine to lysine at
position 292, suggesting a potential for reduced drug binding efficacy. We have performed molecular
dynamics simulations of oseltamivir, zanamivir and peramivir bound to H7N9, H7N9-R292K, and a
structurally related H11N9 neuraminidase. They show that H7N9 neuraminidase is structurally
homologous to H11N9, binding the drugs in identical modes. The simulations reveal that the R292K
mutation disrupts drug binding in H7N9 in a comparable manner to that observed experimentally for
H11N9-R292K. Absolute binding free energy calculations with theWaterSwapmethod confirm a reduction
in binding affinity. This indicates that the efficacy of antiviral drugs against H7N9-R292K will be reduced.
Simulations can assist in predicting disruption of binding caused by mutations in neuraminidase, thereby
providing a computational ‘assay.’
O
n the 31st March 2013 Chinese authorities reported the first three cases of a novel influenza virus of
subtype H7N91,2. According to theWorld Health Organisation (WHO), as of 12th August 2013, patients
infected with this strain have been confirmed in China and Taiwan, with 135 cases and 44 fatalities.
H7N9 is an avian influenza virus transmissible from poultry to humans3,4, and while there are only signs of
human-to-human transmission5, its emergence is a serious cause for concern6. H7N9 is the first N9-type influ-
enza to infect humans. This suggests that the general population will have little natural immunity to the virus,
giving the potential for any outbreak to turn into a serious influenza pandemic7. To help understand the virus,
detailed patient and viral genome sequence data from those infected has been made available rapidly and
publicly1,8. The timely release of this data has allowed copious studies of the virus to be performed9–12, providing
scientists and health professionals with an early and detailed picture of this emerging threat. Here we report the
first structural study into the structure and dynamics of a target protein of H7N9 influenza, neuraminidase. Since
2010, inhibitors of neuraminidase are the only class of antivirals recommended by the WHO for prophylaxis of
influenza A and B infections13. Understanding the structure of neuraminidase in H7N9 influenza, and its inter-
actions with available drugs is required to monitor the emergence of drug-resistant strains, and to inform the
development of new treatments.
Themain drugs used for antiviral treatment of H7N9 are the neuraminidase inhibitors oseltamivir (TamifluH),
zanamivir (RelenzaH) and peramivir14. These drugs provide the first line of defence against H7N9, until a vaccine
can be developed9. The structures of these drugs, together with the location of important functional group
substituents are shown in figure S1 in supporting information. Oseltamivir and zanamivir have been widely
deployed in past influenza outbreaks15, with large stockpiles built up by several governments16,17. Oseltamivir is
taken orally, zanamivir via a nasal spray, while peramivir is newly licensed in only a small number of countries,
and must be taken via injection13. Initial laboratory tests of drug binding, and successful treatment of H7N9
patients with oseltamivir in the field, suggest that the drugs are effective against H7N9 neuraminidase. However,
neuraminidase is known to be capable of mutating to a multitude of drug-resistant forms13,18,19. It is important to
be able to predict whether any of the changes in sequence observed between the samples of H7N9 collected lead to
structural changes in neuraminidase that could disrupt drug binding, and therefore provide early markers of
emerging drug resistance. Here we show how computational assays can be used to predict and rationalize how
differences in the collected sequences of H7N9 affect drug binding at the molecular level. This demonstrates how
computational assays can complement the collection and publication of neuraminidase sequences and other
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experimental and clinical work, by providing a rapid screen to test for
disruption of drug binding mode and reduction of drug binding
affinity. The results also provide insight into how changes in
sequence disrupt drug binding, thereby providing structural
information that will be useful in the design of the next generation
of neuraminidase inhibitors.
Complete viral genomes of samples of H7N9 from patients, birds
and the environment have been sequenced and made publicly avail-
able via the Global Initiative on Sharing All Influenza Data (GISAID
EpiFluTM) database (www.gisaid.org). The four sequences available at
the start of this study (A/Shanghai/1/2013, A/Shanghai/2/2013, A/
Anhui/1/2013 and A/Hangzhou/1/2013) contain neuraminidases
that show high sequence similarity to many N9 type strains.
Analysis showed high similarity to H11N9 neuraminidase (A/
Tern/Australia/G70C/1975), with the sequences differing by only
20 amino acid residues in the ‘head’ of the protein (residues 83–
468,18 95% sequence identity). H11N9 neuraminidase has been well
studied, with crystallographic structural data available of it bound
with all of the available neuraminidase antivirals. Figure 1 shows the
approximate spatial location of key active site residues in the head
region of neuraminidase in relation to the main functional groups of
the antiviral drugs. All of the four sequences of H7N9 are identical in
the head region, with the exception of A/Shanghai/1/2013, which
differs only by a single substitution of arginine to lysine at position
292 (H7N9-R292K, using N2 numbering: see table S1 in supporting
information). All of the differences in sequence between H7N9 and
H11N9 neuraminidase are far from the enzyme active site (figure 2).
However, the arginine to lysine change in H7N9-R292K is in the
active site, and involves a residue that is known to form a salt bridge
with the carboxylate group of each of the antivirals (figure 2). The
R292K mutation is known to confer drug-resistance in many strains
of influenza20–22. Studies ofN9 neuraminidase fromH11N9 influenza
(in a reassortant H1N1 virus, NWS/G70C) show that the R292K
mutation confers drug resistance. Experimental binding assays of
this neuraminidase reveal that the mutation reduces the binding
affinity of oseltamivir and peramivir by several orders of magnitude,
but only has a small effect on the binding of zanamivir20–22. The
experimental ratio of the mutant to wildtype IC50s of the drugs
are: oseltamivir 6,50020, zanamivir 5520 and peramivir 1,00021. As
the R292K mutation reduces binding affinity in H11N9 neuramini-
dase, it is important to investigate whether R292K affects drug bind-
ing to H7N9.While the presence of the R292K substitution indicates
the potential for the H7N9-R292K strain to show disrupted drug
binding, it is not possible from sequence data alone to give a defin-
itive prediction. Certainly, knowledge of the sequence alone does not
provide sufficient information to predict the magnitude of any
reduction in binding affinity. To answer these questions, we have
performed computational assays involving multiple 70 nanosecond
(ns) molecular dynamics simulations of oseltamivir, zanamivir and
peramivir bound to H11N9, H7N9 and H7N9-R292K neuramini-
dase, together with absolute binding free energy calculations using
the WaterSwap method23. WaterSwap calculates condensed phase
absolute protein-ligand binding free energies using a dual topology
reaction coordinate that swaps the ligand with an equivalent volume
of water in the protein binding site. The advantage of WaterSwap is
that it allows calculation of absolute binding free energies. This sim-
plifies investigation of the affect of protein mutation on binding
compared to relative binding free energy methods, as differences in
absolute binding free energies capture changes in binding mode of
the ligand upon proteinmutation. This assay required approximately
two weeks of computation, using readily accessible compute
resources. The results indicate that molecular dynamics simulations
coupled with binding affinity calculations with WaterSwap can pro-
vide a rapid and cheap predictive assay to detect disrupted drug
binding in neuraminidase in emerging influenza strains.
Results
H11N9 neuraminidase has been studied extensively, with X-ray
structures available of it bound to oseltamivir (PDB code 2QW-
K20), zanamivir (1NNC24) and peramivir (1L7F21). The high sequence
identity (95%) of H7N9 to H11N9 allowed us to use in-silico point
mutations from these crystallographic structures to construct struc-
tural models of each of the drugs bound to both H7N9 and H7N9-
R292K. A computational assay involving nine molecular dynamics
simulations was performed using these models: oseltamivir, zanami-
vir and peramivir bound to H11N9, H7N9 and H7N9-R292K neur-
aminidase. The simulations were run with explicit solvent. Using
graphics processors (GPUs), it was possible to simulate 70 nanose-
conds of dynamics of each system within one week (three simula-
tions per neuraminidase strain, 630 ns in total in seven days).
WaterSwap23 absolute binding free energy calculations of the three
drugs bound to H7N9 and H7N9-R292K followed these, using start-
ing structures taken every 10 ns from 20–70 ns from the dynamics
simulations. These calculations were completed in one week, on a
Figure 2 | Oseltamivir bound to H7N9-R292K neuraminidase. This
initial computational model was built by point mutating individual
residues of H11N9 neuraminidase bound to oseltamivir (PDB structure
2QWK20) to match the sequence of H7N9-R292K. Residues that differ
from the reference H11N9 neuraminidase are shown in dark cyan, with the
R292K lysine residue highlighted in red. This structure provides the
starting point for the H7N9-R292K oseltamivir-bound simulation (see
Methods section for more details).
Figure 1 | Schematic showing the approximate spatial location of the
active site residues of neuraminidase in relation to the main functional
groups of the antiviral compounds (see figure S1 for the chemical
structure of the drugs). Residues that form direct interactions with the
drugs are drawn inside the outer circle. The R292 residue is shown in red.
Residues are numbered using N2 numbering.
www.nature.com/scientificreports
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small compute cluster (36 binding calculations using 36 compute
nodes). This shows that useful results can be delivered on the
timescale of a few days, using relatively modest compute resources.
The simulations provide structural understanding of the molecular
interactions between the proteins and the drugs, enabling analysis of
the effects of mutation on protein dynamics and drug binding25.
Structural analysis of the effect of point mutation on the structure
of neuraminidase was performed using calculation of root mean
square fluctuations (RMSF) and deviations (RMSD) (see figure S2–
S5 in supporting information), and visual inspection of the protein
backbone (figures S3–S5). Analysis of RMSF show that the point-
mutated residues show similar fluctuations in the H7N9 and H7N9-
R292K trajectories to those seen in the H11N9 trajectories. There are
no significant peaks, indicating that the point-mutated residues are
fluctuating around a stable conformation, and are not triggering any
large structural changes in the backbone of the proteins. Combined
with analysis of RMSD and visualization of the protein backbone,
this shows that there is little difference in protein dynamics and
global conformation between H7N9, H7N9-R292K and H11N9.
The structure of H7N9 and H7N9-R292K neuraminidase is revealed
to be homologous to that forH11N9, with the differences in sequence
having negligible effect. While the protein backbone structure of
H7N9 and H7N9-R292K shows high similarity to H11N9, the
change from arginine to lysine inH7N9-R292K significantly disrupts
the binding mode of the three drugs. This disruption is structurally
similar to the disruption observed experimentally for the binding of
the drugs to H11N9-R292K20,21, and is discussed in detail in the
following sections.
Oseltamivir complexes. Visualisation and analysis of the simula-
tions shows that the twenty point mutations necessary to create
the H7N9 model have a negligible effect on the structure and
dynamics of neuraminidase, with H7N9 revealed to be structurally
homologous to H11N9. Visualization of oseltamivir in the active site
reveals the same picture. The oseltamivir-bound simulations show
high similarity between the binding modes of the drug to H7N9 and
H11N9 neuraminidase (figure 3a). There is excellent agreement
between the two simulations, and also with the crystallographic
structure. This helps validate the simulation and provides confi-
dence in the conclusion that H7N9 and H11N9 neuraminidase are
structurally similar. While there is excellent agreement between the
binding mode of oseltamivir in the H7N9 and H11N9 simulations, a
different picture is revealed for H7N9-R292K. The change from
arginine to lysine significantly disrupts binding of oseltamivir.
Instead of forming a salt bridge to the carboxylate group, as
observed in the H11N9 X-ray crystal structure, and in the H11N9
andH7N9 simulations (figure 3a), lysinemoves to disrupt binding of
the hydrophobic bulky group of the drug (figure 3b). The bulky
group rotates up and moves out of the hydrophobic pocket. This is
in strong agreement with the X-ray structure of oseltamivir bound to
the R292K mutant of H11N9, which is shown in figure 3b for
comparison (PDB code 2QWE20). The rotation of the bulky group
can be monitored by measuring the angle between it and the plane of
the central ring of oseltamivir. In the case of H11N9 and H7N9,
during simulation, the bulky group points downwards, fluctuating
between angles of 230u to 290u relative to the ring (figure S6 in
supporting information). In contrast, in H7N9-R292K, the bulky
group points upwards, fluctuating between angles of 10u to 40u, in
agreement with the angle of 20u observed in the H11N9-R292K X-
ray structure (figure S6). Disruption of drug binding is confirmed by
the WaterSwap calculations23, which show that the R292K mutation
reduces the binding affinity of oseltamivir to neuraminidase by 3.06
1.2 kcalmol21 (a table of all of the binding free energies is provided in
table S2).
Zanamivir complexes.As seen for oseltamivir, the zanamivir-bound
simulations confirm that H7N9 and H11N9 neuraminidase are
structurally homologous, with little difference seen between the
binding modes of zanamivir to the two proteins (figures 4a and
4b). In addition, the simulation of zanamivir bound to H11N9 neu-
raminidase reproduces the crystallographic structure well, giving
confidence in the computational model. The H7N9-R292K
simulation shows that the change from arginine to lysine signifi-
cantly disrupts binding of the drug. In the H11N9 and H7N9 neura-
minidases, arginine interacts directly with both the carboxylate
group and the hydrophilic bulky group of zanamivir. In contrast,
the smaller size of lysine compared to arginine means that it can
only interact directly with one of these groups. In the H7N9-
R292K simulation, lysine292 moves from the carboxylate group to
form a hydrogen bond with the bulky group of zanamivir (figure 4c).
This is seen in the distance plots in figure 4, which show the distance
between the heavy atoms of the arginine/lysine and the carboxylate
and bulky groups of zanamivir in simulations of the three enzymes.
Hydrogen bonding of lysine to only the bulky group causes a change
in binding mode of zanamivir in H7N9-R292K neuraminidase. This
is shown clearly by comparing figures 4a–4c, which are visualized
from the same viewpoint. This change in binding mode agrees with
experimental structural studies of H11N9-R292K, in which lysine-
292 is seen to hydrogen bond with the bulky group, and zanamivir
shifts binding mode20. WaterSwap calculations predict that this
change in binding mode is accompanied by a reduction in binding
Figure 3 | Structure of oseltamivir bound to (a) H7N9 and (b) H7N9-R292K neuraminidase. In cyan is shown the experimental X-ray structure of
oseltamivir bound to (a) H11N9 (2QWK20) and (b) H11N9-R292K (2QWE20), while in white is shown a representative snapshot taken from simulation.
The average location of oseltamivir and arginine/lysine during the simulation is shown using isosurfaces, with the volume of space occupied on average
during 90% (solid yellow) and 60% (transparent yellow) of the trajectory displayed. This shows that lysine in the H7N9-R292K simulation is located to
disrupt binding of the bulky group of oseltamivir, with the bulky group twisted up, out of the bulky group binding pocket. This is in agreement with the X-
ray structure (2QWE) of H11N9-R292K.
www.nature.com/scientificreports
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affinity of 4.4 6 3.1 kcal mol21 for zanamivir to H7N9-R292K
compared to H7N9 neuraminidase.
Peramivir complexes. The peramivir-bound simulations show that
the binding mode of the drug to H7N9 and H11N9 neuraminidase is
similar, reinforcing the conclusion that H7N9 is homologous with
H11N9 (figure S7 in supporting information). However, as was
observed for oseltamivir and zanamivir, the change from arginine
to lysine in H7N9-R292K neuraminidase significantly disrupts
binding. The peramivir-bound H7N9-R292K simulation shows
that lysine292 does not interact with the carboxylate group of
peramivir, but instead moves towards the bulky group. This
movement of lysine from interacting with the carboxylate group to
interacting with the bulky group of the drug is seen in all of the
H7N9-R292K simulations, and all of the H11N9-R292K crystallo-
graphic structures. Zanamivir has a hydrophilic bulky group, to
which lysine is able to form favourable hydrogen bonding interac-
tions. Peramivir, like oseltamivir, has a hydrophobic bulky group.
For oseltamivir, interaction with lysine caused the bulky group to be
rotated out of the pocket. For peramivir, the bulky group remained in
the pocket, in agreement with the X-ray structure (1L7H21) of
peramivir bound to H11N9-R292K (figure 5). This structure was
maintained for the first 20 ns of the simulation, until the direct
interactions between peramivir and the D151 and R152 residues
on the 150-loop of neuraminidase were broken. Partial opening of
the 150-loop, and a change of binding mode of peramivir away from
the crystallographic structure followed. The 150-loop is a structurally
important part of neuraminidase, and is known to be capable of
opening and closing in group 1 neuraminidases25–27 While it is less
flexible in group 2 neuraminidases (N2, N3, N6, N7 and N9),
combined experimental/computational studies now suggest that it
does move between a closed and partially opened state28. In previous
work, we demonstrated that opening of the 150-loop can be seen in
timescales comparable to these simulations, and was indicative of
reduced binding affinity caused by a drug resistant mutation25. A
change of binding mode and partial opening of the 150-loop was
not observed in the simulations of peramivir binding to H11N9 or
H7N9 neuraminidase. WaterSwap23 binding calculations indicate
that the change in binding mode reduces the binding free energy
of the drug. The average binding free energy of peramivir to
neuraminidase calculated from structures taken between 20–40 ns
from the H7N9-R292K trajectory is 2.4 6 2.5 kcal mol21 lower than
that for the H7N9 trajectory. The difference in average binding free
energy after the change in bindingmode (50–70 ns) ismuch larger, is
9.7 6 2.5 kcal mol21.
Discussion
Computational assay of drug binding to H11N9, H7N9 and H7N9-
R292K neuraminidase shows that the differences in sequence
between H11N9 and H7N9 have negligible impact on protein struc-
ture and drug binding, and that the neuraminidases from these
strains are highly homologous. The structure developed in this study
is thus likely to be a good model for H7N9 neuraminidase, providing
a good foundation for further study of protein-drug interactions
while a crystallographic structure remains unavailable. In addition,
simulations show that the R292K substitution inH7N9-R292K neur-
aminidase disrupts binding of each of the currently approved neur-
aminidase antiviral compounds, suggesting weakened binding. This
disruption is comparable to that observed experimentally between
H11N9 and H11N9-R292K neuraminidase20,21. Waterswap calcula-
tions23 predict that this disruption, involving loss of specific interac-
tions between the protein and the drugs, is associated with a
reduction in binding free energy. This result is in line with the results
of a recent experimental study29 that shows that the R292Kmutation
reduces the binding affinity of each of the drugs to H7N9
neuraminidase.
In addition to providing goodmodels of the structure ofH7N9 and
H7N9-R292K neuraminidase, and a prediction of the reduction in
binding affinity caused by the R292K mutation, this study demon-
strates the recent advances in speed, accuracy and capability of mod-
ern molecular simulation techniques. While sequence data alone can
only suggest that a strain of influenza may show weaker drug bind-
ing, computational structural and free energy studies can provide
strong evidence. The necessary extensive molecular simulations
can now test the effects of mutations rapidly: the required simula-
tions can be completed within two weeks of a sequence being made
publicly available with current computer resources (setup and run-
ning of the dynamics simulations here took one week, with a further
Figure 4 | Simulation structures of zanamivir bound to (a) H11N9, (b) H7N9 and (c) H7N9-R292K neuraminidase. All figures are rendered from the
same viewpoint, showing that the lysine residue in H7N9-R292K hydrogen bonds with the bulky group of zanamivir, shifting the drug up and to the right
compared to H11N9 and H7N9. The figures show representative snapshot structures from the simulations, with the average location of zanamivir and
arginine/lysine shown using isosurfaces, with the volume of space occupied during 90% (solid yellow) and 60% (transparent yellow) displayed. The
graphs show the distance between the arginine/lysine and the carboxylate group (D1) and bulky group (D2) on zanamivir. Distances are shown on a color
scale from 2–8 A˚, with blue-green values indicating the presence of a hydrogen bond or salt bridge. These show that while arginine interacts directly with
both the carboxylate and bulky groups of zanamivir, lysine hydrogen bonds only sporadically with the bulky group.
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 3 : 3561 | DOI: 10.1038/srep03561 4
week required for theWaterSwap calculations). Molecular dynamics
simulations (using e.g. GPUs), coupled with binding calculations
(using methods such as WaterSwap23) can now provide a rapid,
predictive and practical assay on a useful timescale. This approach
will be useful for neuraminidase and also other drug targets (e.g.
enzymes) for which good quality experimental structures of the
unmutated target exist and sequence data for emerging mutants
typically becomes available before samples of the protein can be
isolated for experimental assay or structural study. Molecular simu-
lations of this type will complement experimental studies of emer-
ging drug-resistance, and will assist in predicting possible deleterious
mutations at the molecular level. Simulations can providing rapid
predictions of the effects of changes in sequence, in particular pre-
dicting changes in structure and drug binding affinity, on a useful
timescale. Molecular simulations can therefore now provide an assay
to assist in predicting disruption of drug binding caused by the
emergence of novel strains and new mutants of neuraminidase.
Methods
The H7N9 neuraminidase sequences were downloaded from the GISAID EpiFluTM
database (www.gisaid.org) and aligned using Clustal Omega (www.clustal.org).
H7N9 neuraminidase sequences A/Shanghai/1/2013 (EPI_ISL_138737),
A/Shanghai/2/2013 (EPI_ISL_138738), A/Anhui/1/2013 (EPI_ISL_138739) and A/
Hangzhou/1/2013 (EPI_ISL_138977) were aligned against the H11N9 sequence of A/
Tern/Australia/G70C/1975, obtained from the X-ray structure 2QWK20 downloaded
from the Protein Data Bank (PDB). This showed 95% sequence similarity in the head
region (residues 83–468 using N2 numbering), with the Shanghai/2, Anhui/1 and
Hangzhou/1 strains all identical in this region, and Shanghai/1 differing by a single
amino acid (arginine to lysine at position R292, see table S1 in supporting informa-
tion). X-ray structures of H11N9 A/Tern/Australia/G70C/1975 neuraminidase
complexed with oseltamivir (2QWK20), zanamivir (1NNC24) and peramivir (1L7F21)
were downloaded from the PDB and used as the starting structures of the H11N9
simulations. Copies of these were point mutated in-silico using the LEaP module of
AMBER 12 to obtain the starting structures for the H7N9 and H7N9-R292K simu-
lations. Mutated residues were built with starting geometries that matched the native
residues. Each of the nine starting structures (H11N9, H7N9 and H7N9-R292K, each
bound to oseltamivir, zanamivir and peramivir) were processed and simulated using
the same protocol, which we have validated in a previous paper25. The coordinates of
all crystallographic water and calcium ion molecules were retained. Hydrogen atoms
were added independently for each system using LEaP, with an ionization state for
each amino acid residue predicted by PROPKA30. Hydrogen atoms were added to
oseltamivir, zanamivir and peramivir via a HF/6-31G* optimization using Gaussian
03. LEaP was used to solvate each system independently in a TIP3P31 water box of
approximate volume 803 803 80 A˚3, with chloride counter-ions added to neutralize
the system. The FF03.r1 forcefield32 implemented in AMBER 12 was used to model
neuraminidase. The atomic charges of the drugs were calculated based on the
electrostatic potential from single point HF/6-31G* calculations using Gaussian 03,
and fitted using the RESP module in AMBER 12. Parameters for the drugs were
assigned from the generalized AMBER forcefield (GAFF)33 using Antechamber, with
the parameters for oseltamivir and zanamivir tested in our previous validation
study25. Energy minimization was performed to optimize the position of added
hydrogen atoms and water molecules in each system using the pmemd.CUDA
module in AMBER 12 (version 12.1, bugfix.9, released August 2012)34. The mixed
single-precision/fixed precision (SPFP) version of pmemd.CUDA was employed.
Particle-Mesh Ewald (PME) was used to account for long-range electrostatics, with a
10 A˚ real space cutoff, with the same cutoff used for the Lennard Jones potential.
SHAKE was used to constrain bonds involving hydrogen. After minimization,
molecular dynamics (MD) simulations were carried out also using pmemd.CUDA. A
time step of 2 fs was used, with the simulation divided into thermalization, equilib-
ration and production phases. In the thermalization step, the temperature was
increased linearly to 310 K over a period of 100 ps using canonical (NVT) dynamics.
A Langevin thermostat was used tomaintain temperature, using a collision frequency
of 5 ps21. Next, the system was equilibrated for a further 100 ps of NVT dynamics,
then a further 800 ps of isothermal-isobaric (NPT) dynamics, with a Langevin
thermostat used to maintain a temperature of 310 K, and the isotropic pressure
scaling algorithm implemented in pmemd.CUDA used to maintain the pressure at 1
bar, using a pressure relaxation time of 1 ps. Visual inspection of each system together
with monitoring of RMSD confirmed that the starting structures closely matched the
original crystal structures. Each system was then equilibrated for a further 20 ns at
310 K and 1 bar, before a further 50 ns of NPT dynamics was generated during the
production phase. Thermalization, equilibration and production was carried out
using a singleM2090 nVidia Tesla GPU per simulation, with production dynamics of
each,60,000 atom system running at a rate of approximately 11 ns of sampling per
day. The simulations were run in 1 ns blocks, with coordinates of all atoms saved
every 10 ps. This generated approximately 3.7 GB of compressed data per simulation.
In total, running the simulations required dedicated access to 9 M2090 GPUs for
seven days, and generated about 33 GB of compressed data. WaterSwap23 calcula-
tions were performed using the WSRC module in Sire, with calculations using the
same forcefield parameters and solvent model as the dynamics simulations. Six
WaterSwap calculations were performed for each drug-neuraminidase complex, with
the difference in mean average absolute binding free energy between the H7N9 and
H7N9-R292K simulations reported (raw data supplied in table S2 in supporting
information). Errors were estimated from the standard errors on these averages.
WaterSwap23 calculations used starting structures taken from snapshots every 10 ns
between 20–70 ns from each of the H7N9 and H7N9-R292K trajectories. Absolute
binding free energies were calculated using replica-exchange thermodynamic integ-
ration35 over 16 l windows (0.005, 0.071, 0.137, 0.203, 0.269, 0.335, 0.401, 0.467,
Figure 5 | Structures of peramivir bound toH7N9-R292Kneuraminidase, showing representative snapshots and the average structure between (a) 20–
40 ns and (b) 40–70 ns. The average location of peramivir and lysine is shown using isosurfaces, with the volume of space occupied during 90%
(solid yellow) and 60% (transparent yellow) of the two time periods of the simulation displayed. The H11N9-R292K X-ray structure (1L7H21) is shown in
cyan. This shows that the simulation closely matched the X-ray structural data in the first part of the simulation. After 40 ns, the 150-loop partially
opened, leading to a loss of interaction between peramivir and D151/R152, and a change in binding mode of the drug. The shortest distance between the
hydrogen bond donors and acceptors of peramivir (guanidinium and hydroxyl groups) to the D151 and R152 residues on the 150-loop are shown on a
color-scale from 2–8 A˚, with blue-green values indicating the presence of a salt bridge or hydrogen bond. This shows that the interactions between
peramivir and the two 150-loop residues were lost at approximately 45 ns. Equivalent figures for peramivir bound to H11N9 and H7N9 neuraminidase
are given in figure S8 in supporting information.
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 3 : 3561 | DOI: 10.1038/srep03561 5
0.533, 0.599, 0.665, 0.731, 0.797, 0.863, 0.929, 0.995) over the WaterSwap reaction
coordinate. 30millionMonte Carlomoves were performed for each window, with the
free energy gradient averaged over the last 20 million steps. Simulations used the ‘‘Set
A’’ soft-core parameters23, with a 15 A˚ coulomb and Lennard Jones non-bonded
cutoff, the shifted-force cutoff36 used to account for long-range electrostatics, and a
reflection sphere used to constrain sampling to within a 15 A˚ radius of the drug.
Trajectories were visualized using VMD 1.9.137. Visualisation and analysis was based
on alignment of the trajectories against the protein backbone of the 2QWK structure,
using the RMSDTrajectory Tool in VMD. Average occupations were generated using
the VOLMAP tool in VMD, using a 0.5 A˚ grid, and calculating occupancy of all of the
atoms from arginine/lysine 292 and oseltamivir, zanamivir or peramivir. Atoms were
treated as hard spheres, with occupations calculated every 10 ps between 20–70 ns
and averaged. All structural analysis was performed on frames taken every 10 ps from
20–70 ns from the trajectories. RMSDs were calculated using the RMSD tool in
VMD, while RMSFs were calculated using the g_rmsf component of GROMACS.
Interatomic distances were calculated using Wordom38, with distances between all
equivalent donor-acceptor pairs evaluated, and a custom Python script used to select
the minimum distance. These were processed and plotted using a custom Python
script and Gnuplot, using a color scale capped from 2 A˚ (blue) to 8 A˚ (red). Distances
greater than 8 A˚ were drawn using the same color as 8 A˚, while distances less than
2 A˚ were drawn using the same color as 2 A˚. The angle between the bulky group of
oseltamivir and its central ring was calculated using VMD, using the atoms high-
lighted in figure S6 of supporting information.
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